ClinicalTrials.gg
Not yet recruitingNCT07936708Updated Nov 13, 2026

SA030 Injection in Healthy Participants

A Phase 1 interventional study of Experimental: 100mg and Experimental: 200mg in Weight Management, sponsored by Suzhou Siran Biotechnology Co.,Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Suzhou Siran Biotechnology Co.,Ltd. · Phase 1, Interventional, and Treatment

How we know

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single ascending doses of SA030 injection in healthy participants. The planned dose levels include 100 mg, 200 mg, and 400 mg, with 8 eligible participants enrolled in each dose group.

All participants receive a single administration of the study drug on Day 1 (D1). In each dose group, the first 2 participants are enrolled as sentinel participants and randomized at a 1:1 ratio to receive either SA030 injection or placebo. After a 5-day safety observation period and favorable safety assessment by the investigator, the remaining 6 participants in the group will be enrolled and randomized at a 5:1 ratio to receive SA030 injection or placebo.

For dose escalation, at least 6 out of 8 participants in each dose group must complete the 14-day safety observation period (up to Day 15 [D15]). Subsequent dose escalation to the next higher dose level can only be initiated after safety review and approval by the Safety Review Committee (SRC).

02

Conditions studied

  • Weight Management

Keywords

  • SA030 injection
  • healthy participants
  • Phase 1
  • single ascending dose
03

In context

Lead sponsor

Suzhou Siran Biotechnology Co.,Ltd. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged 18 to 55 years, with a of 25-40 kg/m².
  • Healthy participants as determined by medical history, physical examination, vital signs, and laboratory assessments.
  • Willing to use effective and have no pregnancy plans from screening to 6 months after study drug administration and/or throughout the study, with no intent to donate sperm or ova.

Exclusion criteria

Exclusion Criteria:

  • Medical history:

    • Nervous, cardiovascular, hematologic/lymphatic, immune, gastrointestinal, renal, respiratory, endocrine disorders, history of , or psychiatric/psychological conditions
    • Has hypertension at screening (blood pressure ≥150/95 mmHg), diabetes mellitus (FPG ≥7.0 mmol/L and/or ≥7.0%), hyperlipidemia (LDL-C ≥4.9 mmol/L or TG ≥500 mg/dL (5.65 mmol/L)), or gout.
    • Has a history of bleeding disorders, recent active bleeding, or bleeding risk; or has coagulation abnormalities deemed clinically significant by the Investigator at screening.
    • Tests positive for , , , or syphilis (positive Treponema pallidum, excluding those with negative RPR).
    • Has undergone major surgery within 6 months prior to screening, or plans to undergo surgery during the study period.
    • Has severe infection or trauma within 4 weeks prior to screening.
    • Has clinically significant hepatic space-occupying lesions, gallbladder lesions, pancreatic or renal abnormalities identified on abdominal ultrasound at screening.
    • Has severe allergic diathesis.
    • Has prior severe intolerance to subcutaneous injection.
    • Has skin abnormalities at injection sites.
    • Has risk factors for TdP, requires concurrent use of /QTc-prolonging / TdP-inducing drugs, or has high-risk bundle branch block.
  • Has clinically significant laboratory abnormalities at screening as judged by the Investigator.
  • concomitant medications:

    • Has received within 1 month prior to screening, or plans to receive live attenuated vaccine during the study period.
    • Has used any prescription drugs, herbal medicines, or over-the-counter medications within 14 days prior to administration of the product.
    • Has used any over-the-counter medications, herbal medicines or dietary supplements that may significantly affect body weight or metabolism within 1 month prior to screening.
    • Has participated in another drug clinical trial within 3 months prior to treatment in this study or within 5 half-lives of the other investigational product ; or has prior use of siRNA or antisense oligonucleotide drugs within 6 months prior to administration of the study drug.
  • Other

    • Has non-physiological blood loss ≥ 400 mL within 1 month prior to screening (including trauma, blood sampling, blood donation), or plans to donate blood during the study or within 30 days after study drug administration.
    • Has weekly alcohol intake >14 units within 3 months prior to screening ; or has a positive alcohol breath test on the day before dosing ; or is unable to abstain from alcohol during the in-hospital study period.
    • Has current or history of illicit drug use/substance abuse, or tests positive on urine drug screen on the day prior to dosing.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    SA030 Injection, 100 mg

    Single subcutaneous injection of SA030 at 100 mg dose, one-time administration.

    Drug: Experimental: 100mg

  • Experimental
    SA030 Injection, 200mg

    Single subcutaneous injection or SA030 at 200 mg dose, one-time administration.

    Drug: Experimental: 200mg

  • Experimental
    SA030 Injection, 400mg

    Single subcutaneous injection or SA030 at 400 mg dose, one-time administration.

    Drug: Experimental: 400mg

  • Placebo comparator
    placebo

    Single subcutaneous injection of placebo, one-time administration.

    Drug: Placebo

Interventions

  • DrugExperimental: 100mg

    Single subcutaneous injection of SA030 injection at a dose of 100 mg, one-time administration on Day 1.

  • DrugExperimental: 200mg

    Single subcutaneous injection of SA030 injection at a dose of 200 mg, one-time administration on Day 1.

  • DrugExperimental: 400mg

    Single subcutaneous injection of SA030 injection at a dose of 400 mg, one-time administration on Day 1.

  • DrugPlacebo

    Single subcutaneous injection of placebo, one-time administration.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Approximatly 9 months

  2. Number of participants with clinically significant laboratory abnormalities

    Time frame: Approximatly 9 months

Secondary outcomes

  1. Peak plasma concentration (Cmax)

    Time frame: Pre-dose, multiple timepoints post-dose up to D15

  2. Time to peak plasma concentration (Tmax)

    Time frame: Pre-dose, multiple timepoints post-dose up to D15

  3. Plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-t)

    Time frame: Pre-dose, multiple timepoints post-dose up to D15

  4. Elimination half-life (t1/2)

    Time frame: Pre-dose, multiple timepoints post-dose up to D15

  5. Changes in BMI

    Time frame: baseline, up to 9 months

  6. Changes in body fat content

    Time frame: baseline, up to 9 months

  7. Changes in hepatic fat content

    Time frame: baseline, up to 9 months

  8. Changes in ALK7 expression

    Time frame: baseline, up to 9 months

  9. Number of participants with anti-SA030 antibodies (immunogenicity)

    Time frame: baseline, up to 9 months

  10. Change in QTcF relative to baseline and relative to placebo compared to baseline

    Time frame: Pre-dose, multiple timepoints post-dose up to Day 5

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2026
First posted
Nov 13, 2026
StartEst.
Oct 16, 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07936708
Lead sponsor
Suzhou Siran Biotechnology Co.,Ltd.
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Oct 16, 2026 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Hong Zhang
Contact
zhanghong@siranbio.com
+86 15298351869

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion